Lucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest

Lucid Diagnostics (LUCD), subsidiary of PAVmed (PAVM), has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method of using methylation of the cyclin-A1 gene to help detect esophageal precancer and cancer, a key component of its EsoGuard Esophageal DNA Test. Lucid Diagnostics markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Lucid holds the exclusive worldwide license to commercialize this technology. The successful transfer of the assay from the academic research laboratory and its subsequent commercialization was the result of collaboration between Lucid and Case Western Reserve University.